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Purpose: Endovascular stent graft repair of abdominal aortic aneurysms (AAA) with the Endologix Powerlink System
(Endologix, Inc, Irvine, Calif) has been shown to be a safe and effective alternative to open surgery in patients having an
aortic neck diameter of up to 26 mm. We assessed the safety and effectiveness of AAA repair in patients with wide aortic
necks (up to 32 mm in diameter) using the Powerlink XL System.
Methods: Between September 2005 and June 2008, a prospective, multicenter, pivotal US Food and Drug Administration
trial of the Powerlink XL System for endovascular aneurysm repair was conducted at 13 centers. Using a sizing algorithm
based on computed tomography scan (CT)-based measurements, a total of 78 patients (N  60 [pivotal trial]; N  18
[continued access]) presenting with AAA and an infrarenal aortic neck up to 32 mm in diameter received a bifurcated
stent graft via anatomical fixation at the aortoiliac bifurcation and proximal sealing with a Powerlink XL infrarenal
proximal extension stent graft. Postoperatively, results were assessed with contrast-enhanced CT scans and abdominal
x-rays at one, six, and 12 months, with continued annual follow-up to five years.
Results: Predominantly male (91%), patients presented at a mean age of 73  8.6 years with mean maximum aortic neck
and AAA diameters of 31  1.9 mm (range, 25 to 32 mm) and 5.7  1.0 cm (range, 4.3 to 10 cm), respectively.
Challenging infrarenal aortic neck anatomy, defined as the presence of severe thrombus and/or reverse taper, was present
in 85% of patients. Technical success was achieved in 98.7% of patients, with one patient requiring femoral-femoral bypass
intraoperatively. Aneurysm exclusion was achieved in 100% of patients over a mean procedure time of 129  66
minutes. Patients were discharged at a mean of 2.2 days postoperatively. At the one-month CT scan, the independent
core lab identified a Type II endoleak in 13 patients, distal Type I and Type II endoleak in one patient, and unknown
endoleak in three patients. At 30 days, there were no deaths, conversions, ruptures, or migrations. Through one year
follow-up, Type II endoleak predominated (9/10 patients with endoleak), with one proximal Type I and no Type III,
IV, or unknown endoleak; no conversions, ruptures, or migrations have been observed. The one-year all-cause mortality rate
was 6.4%, with 100% freedom from aneurysm-relatedmortality. Secondary procedures were performedwithin one year in five
patients (6.4%) for treatment of proximal Type I endoleak (n 2), proximal Type I/Type II endoleak (n 1), and distal Type
I endoleak (n  2). Reduced or stable aneurysm sac diameter at one year is observed in 96% of patients.
Conclusions: The combination of an anatomically-fixed Powerlink bifurcated stent graft and a Powerlink XL infrarenal
proximal extension appears safe and effectively excludes aneurysms in patients with wide aortic necks. These results
suggest that fixation at the aortic bifurcation can provide secure fixation for patients with large diameter diseased
proximal aortic necks. ( J Vasc Surg 2009;50:979-86.)In prospective, multicenter, controlled clinical trial ex-
perience with mid- to long-term follow-up, the Powerlink
System (Endologix, Inc, Irvine, Calif) has been shown to be
a safe and effective endovascular treatment option for pa-
tients with abdominal aortic aneurysms (AAA) and aortic
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doi:10.1016/j.jvs.2009.05.057necks up to 26 mm in diameter.1-5 To enable the treatment
of patients with large aortic necks up to 32mm in diameter,
and to inhibit distal migration, an alternative approach
coupling a Powerlink bifurcated stent graft placed at the
aortic-iliac bifurcation and a large diameter Powerlink XL
proximal extension placed to achieve proximal seal was
developed. We report the mid-term results of the pivotal
US Food and Drug Administration trial that was designed
and conducted to evaluate this device and implant tech-
nique combination.
METHODS
Trial design. A prospective, multicenter, single arm
trial of the safety and efficacy of the Endologix Powerlink
XL system was conducted at 13 centers (see Appendix,
online only) according to US Food and Drug Administra-
tion (FDA) regulations and guidelines. The Powerlink XL
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since 2002, and has been available in the United States
under an investigational device exemption in the context of
a pivotal US FDA trial with a continued access enrollment
provision. The trial enrolled 60 patients between Septem-
ber 2005 and July 2007, with continuing follow-up for all
patients. To gain additional experience with the device and
implantation algorithm, an additional 18 patients were
enrolled between August 2007 and June 2008 under an
FDA-approved continued access provision. Available data
for this group are limited to early outcomes; with continu-
ing follow-up through five years. Each center obtained
institutional review board approval for human investiga-
tion, and written informed consent was obtained from each
patient. The primary study endpoint was the incidence of
proximal Type I endoleak within one year. The target
proportion for this study was 0.80, with null and alternative
hypotheses given by H0: P  0.80 versus H1: P  0.80,
where P is the proportion of patients with no proximal Type
I endoleak at one year post-implant. Using a sample size of
50 patients, the smallest binomial parameter for which the
upper tail contains 80% or more of the area is 0.922. To
provide an allowance for patients who may be lost to
follow-up, the sample size was increased to 60. Positive
demonstration of the study hypothesis required analysis
using the exact binomial distribution of the observed pro-
portion of patients with no proximal Type I endoleak at one
year post-treatment yielding a one-sided P-value less than
.05. A sensitivity analysis was performed to impute a result
if a patient was missing at one year, confirming the primary
analysis results. The primary safety endpoint was the inci-
dence of major adverse events (MAE) within one year.
MAE was defined as all-cause mortality, aneurysm rupture,
conversion to open repair, secondary procedure, coronary
intervention, myocardial infarction, renal failure, respira-
tory failure, and stroke. Prospectively defined secondary
endpoints include technical success, independent core lab-
oratory evaluations of endoleak, device integrity, patency,
and migration.
Device description and delivery. The Powerlink de-
vice consists of a unibody, self-expanding cobalt chromium
alloy endoskeleton wire without sutures or welds. The
graft, constructed from expanded polytetrafluoroethylene
(ePTFE), resides outside the stent mechanism and is fully
supported by the stent with proximal and distal attachment
using polypropylene suture. Devices used in the trial (Fig 1)
include Powerlink 28mm infrarenal bifurcated devices with
body lengths of 80 or 100mm and limb lengths of 40 or 55
mm (total lengths of 120 to 155 mm), delivered with a 21
Fr coaxial delivery system, and the Powerlink XL 34 mm
infrarenal proximal extension with length of 80 mm, deliv-
ered with a 22 Fr delivery system. Distal extensions were
also available with diameters of 16 to 25 mm. The bifur-
cated device was delivered under fluoroscopic guidance
through one surgically exposed femoral artery and percu-
taneous 9 Fr contralateral access. Bifurcated 21 Fr delivery
system insertion, guidewire placement, heparin anticoagu-
lation, and deployment steps have been previously de-scribed and illustrated.6 Unique to this trial, the device was
deployed such that the bifurcation of the stent graft was
required to be placed at the level of the aortoiliac bifurca-
tion. The delivery system was removed through the central
lumen of the stent graft body and ipsilateral limb. The
proximal aortic extension delivery system was then inserted
over a 0.035” guidewire into the ipsilateral arteriotomy and
through the central lumen of the bifurcated device into the
proximal aorta. Under fluoroscopic guidance, the exten-
sion delivery system outer sheath was retracted, deploying
the stent graft below the most caudal renal artery to achieve
proximal seal. Balloon dilatation of attachment sites was
performed if deemed necessary after completion arteriog-
raphy.
Patient and device selection. Patients with nonrup-
tured infrarenal aortoiliac aneurysms (Table I) under-
went computed tomography (CT) scanning with three-
dimensional reconstruction to assess for study inclusion.
Scans were analyzed by the sites to determine anatomic
suitability for enrollment and ultimately by the core labo-
ratory (M2S, Inc, West Lebanon, NH) to determine base-
line values for analysis. Preoperative catheter angiography
was left to the discretion of the individual operator.
Preoperative measurements of non-aneurysmal aortic
neck diameter and distance from lowest renal artery to the
aortic bifurcation and hypogastric arteries were performed
to determine patient eligibility and bifurcated device op-
tions. When more than one choice of bifurcated device was
available based on the sizing algorithm, physician discretion
was used to determine the selection. While three patients
had a neck diameter of 25 mm at the lowest renal, the more
distal neck ranged from 30 to 32 mm and were considered
appropriate for the trial. Even considering the variable
proximal aortic neck diameters in reverse taper necks, the
proximal cuff was selected to allow 10% to 20% oversizing
of the proximal aortic cuff compared with the aortic diam-
Fig 1. Powerlink 28 mm bifurcated graft with 34 mm Powerlink
XL proximal extension cuff.eter.
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fined as those having more than 3 mm of thrombus around
60% of the circumference of the proximal seal zone; less
than 15 mm length of proximal landing zone; or a taper
greater than 2 mm along the first 15 mm of proximal
landing zone.
Follow-up evaluation. Patients underwent abdomi-
nal plain x-ray studies prior to hospital discharge. Protocol-
specified continued follow-up is at one month, six months,
one year, and annually to five years. At each visit, a physical
exam including serum creatinine analysis, abdominal four-
view x-ray studies (anteroposterior, lateral, left and right
anterior oblique) and contrast-enhanced CT scans were
conducted. Endoleak was defined as the presence of con-
trast material within the aneurysm sac but outside of the
graft material. Migration was defined as 10 mm move-
ment of the proximal end of the graft from the baseline scan
relative to the lowest most renal artery. These studies were
evaluated by each local site and independently by the
central core laboratory.
Statistical analysis. Baseline and procedural continu-
ous, ordinal, and categorical variables are presented de-
scriptively. Early (within 30 days) and late major adverse
events are presented descriptively. Kaplan-Meier survival
estimates were used to analyze rates of mortality and major
adverse events through the follow-up period at exact time
points (ie, one year  365 days). Analysis of the primary
endpoint was conducted using the exact binomial distribu-
tion. Endoleak and aneurysm size data are presented
descriptively. Changes in aneurysm size over time are analyzed
with a paired t test. Statistical significance is considered for
P-values less than .05. All statistical analyses were performed
using SAS software version 8.2 or later (SAS Institute,
Table I. Study inclusion/exclusion criteria
y Proximal infrarenal aortic neck:
- Length 15 mm
- Diameter 23 to 32 mm
- Angle to the AAA sac 60°
y AAA diameter 4.0 cm or rapidly growing
y Iliac diameter 8 mm on ipsilateral side
y Iliac seal zone 15 mm
y Bilateral iliac angle to the aortic bifurcation 90°
y Distance from the most caudal renal artery to the aortic bifurca
and length of bifurcated device body chosen:
Neck diameter 23 to 26 mm 26
RTB1
†
95 mm 
RTB2
‡
115 mm 
y Preservation of at least one hypogastric artery
y Dispensable inferior mesenteric artery
y Serum creatinine level 1.7 mg/dL
y No bleeding or connective tissue disorders
y No contraindication to contrast media
y Not pregnant
y Life expectancy of at least two years
y Provides written informed consent and is willing to comply wit
†If bifurcated device with 80 mm body selected.
‡If bifurcated device with 100 mm body selected.Cary, NC).RESULTS
Enrollment and procedural outcomes. Patient de-
mographic and baseline characteristics are shown in Table
RTB) meets the sizing algorithm based on aortic neck diameter
8 mm 28 to 30 mm 30 to 32 mm
mm 110 mm 115 mm
mm 130 mm 135 mm
ow-up schedule
Table II. Baseline demographics and comorbidities
Characteristic Result
Male gender 71 (91%)
Age, years 73  8.6
Serum creatinine, mg/dL 1.2  0.4
Arrhythmia 20 (26%)
Cancer 23 (29%)
Cerebrovascular disease 17 (22%)
Coagulopathy 4 (5.1%)
Congestive heart failure 16 (21%)
Coronary artery disease 47 (60%)
COPD 33 (42%)
Diabetes 19 (24%)
Family history of AAA 10 (13%)
Gastrointestinal abnormality 32 (41%)
Hypertension 65 (83%)
Hypercholesterolemia 54 (69%)
Liver disease 3 (3.8%)
Peripheral arterial disease 27 (35%)
Prior abdominal surgery 32 (41%)
Prior myocardial infarction 21 (27%)
Prior CABG 22 (28%)
Prior PTCA/stent 45 (58%)
Renal failure 3 (3.8%)
Smoking (ever) 66 (85%)
Valvular disease 9 (12%)
Valve replacement 2 (2.6%)
Results reported as n (% of 78) or mean  standard deviation.
AAA, Abdominal aortic aneurysm; CABG, coronary artery bypass graft;
COPD, chronic obstructive pulmonary disease; PTCA, percutaneous trans-
luminal coronary angioplasty.tion (
to 2
105
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enrolled patients were primarily male (91%) at a mean age
of 73  8.6 years. Prevalent comorbidities included
chronic obstructive pulmonary disease (COPD, 42%), cor-
onary artery disease (60%), hypertension (83%), peripheral
arterial disease (35%) and smoking history (85%). Median
proximal non-aneurysmal neck diameter was 28 mm (prox-
imal) and 31 mm (distal); median neck length and angula-
tion to the aneurysm sac were 24 mm and 38°, respectively.
Patients enrolled in this trial had a larger mean aneurysm
sac diameter than patients enrolled in the original trial
(5.7  1.0 cm vs. 5.1  0.7 cm, P  .001). Moreover, a
substantial number of patients in this cohort were reported
by the core lab with proximal neck characteristics that were
considered challenging for endovascular repair.7,8 Severe
neck thrombus was found in 41% (32/78) of enrolled
patients (example shown in Fig 2). A reverse taper was
found in 69% (54/78) of patients. Either feature was
present in 85% of patients (66/78), while both were
present in 26% of patients (20/78). In addition, a short
proximal neck seal zone of 4 to 13 mmwas present in 15 of
78 patients (19%). Five of these 15 patients had severe
thrombus and nine of these had a reverse taper of 3 to 6
mm.
Per the Society for Vascular Surgery reporting stan-
dards,9 technical success was achieved in 98.7% of patients.
Endovascular repairs were performed with the patient
maintained under general anesthesia (62%), regional or
epidural anesthesia (26%), or local anesthesia (12%). Each
patient received one of four 28mmbifurcatedmodels, with
implant at the aortoiliac bifurcation: 45 patients (58%)
received an 80 mm body device, and 33 patients (42%)
received a 100 mm body device. All patients received a
proximal aortic extension, with 17 patients (22%) anatom-
ically requiring a second extension. Distal extensions were
used in 21 patients (27%).
Measures of clinical utility were consistent in this trial
with those observed in the original Powerlink trial test
Fig 2. An example of a thrombus filled neck that was treated with
shrinkage at 12 months.group. During an average fluoroscopy time of 26  18minutes, mean contrast usage was 126  78 mL. Total
procedure time averaged 129  66 minutes, with mean
estimated blood loss of 356  299 mL. Patients were
discharged from the hospital at a mean of 2.2 days (range,
one to 18 days).
In one pivotal trial case, an inadvertent wire wrap
leading to device limb damage necessitated femoral to
femoral bypass to restore distal flow. Complications attrib-
uted to the procedure include hematoma development at
the percutaneous access site resolved with drainage (n 1),
pseudoaneurysm development at the percutaneous access
site resolved with thrombin injection (n  2), femoral
artery access vessel tear treated with endarterectomy and
patch repair (n  2), and external iliac dissection treated
with angioplasty and stenting (n  1).
The pivotal trial enrolled 60 test patients who have
been followed for a median of 1.2 years. During the con-
tinued access phase, an additional 18 patients were enrolled
and have been followed for a median of 0.3 years. One
month follow-up data are available for all patients. Exclud-
ing five patients who died, two patients who withdrew
voluntarily, two patients who suffered a stroke and were
confined to long-term care facilities and did not undergo
the scheduled CT imaging, one patient who refused the CT
scan (but completed the clinical exam), and 17 continued
access patients who are not yet eligible, one year follow-up
data are available for 51 patients. Longer-term follow-up
data are available over two years in 22 patients, and over
three years in five patients.
Pivotal trial primary endpoint analysis. Within one
year, two proximal Type I endoleaks were observed in the
pivotal trial group, yielding a success rate of 96% (P 
.001). In the first patient, who had a 7 mm reverse taper
neck over the first 5 mm, no intraoperative endoleak was
observed. A proximal Type I endoleak was reported by core
lab at the one year visit, although the aneurysm sac did not
significantly increase in size since the initial implant. The
patient received an additional proximal extension on day
393, with resolution of the endoleak. In the second patient,
intraoperative endoleak was observed and was treated with
ballooning of the attachment point per the instructions for
use, with apparent resolution of the endoleak. The patient
was diagnosed with a proximal Type I endoleak after one
year, although the aneurysm sac did not significantly in-
crease in size since the initial implant. Treatment with a
balloon-expandable Palmaz 5010 aortic stent on day 768
resolved the endoleak. This second failure was attributable
to a thrombus filled, reverse taper neck and inadequate
length to allow for full expansion of the proximal 34 mm
cuff. Both initial failures were then attributed to diseased
proximal aortic anatomy (thrombus-filled, highly angu-
lated conical proximal aortic neck).
Mortality andmajor adverse events. Within 30 days,
no patient death occurred. After 30 days and within one
year, five (6.4%) patients died due to lung cancer (n  2),
multi-organ failure secondary toC. difficile colitis infection
(n  1), myocardial infarction (n  1), and pneumonia
(n  1). None of these deaths was secondary to a proce-
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none is considered aneurysm related. This one-year all-
cause mortality rate (6.4%) is consistent with the all-cause
mortality rate observed in test patients enrolled in the
original Powerlink trial (6.7%). After one year and up to
three years, six patient deaths were reported due to cancer
(n 2), congestive heart failure (n 1), respiratory failure
and sepsis secondary to COPD (n 1), thrombocytopenia
(n  1), and stroke (n  1). As illustrated in Fig 3, the
Kaplan-Meier one-year estimate of freedom from all-cause
mortality is 91%.
As detailed in Table III,three patients suffered a major
adverse event (MAE) within 30 days post-procedure: respi-
ratory failure secondary to pre-existing congestive heart
failure (n 1); renal failure secondary to pre-existing renal
insufficiency attributed to contrast exposure (resolved fol-
lowing in-patient dialysis for two days), and secondary
intervention for distal Type I endoleak (n  1). No peri-
operative aneurysm rupture, conversion to open repair,
coronary intervention, myocardial infarction, or stroke was
observed. After 30 days and within one year, no aneurysm
rupture, conversion to open repair, or coronary interven-
tion has been reported. Late MAE included acute myocar-
dial infarction treated medically (n  1), renal failure (n 
3), respiratory failure secondary to lung cancer (n  1),
stroke (n  2), and secondary intervention for Type II
endoleak (n  1 [with subsequent proximal Type I inter-
vention during year 2]) or proximal Type I endoleak (n 
2). Mean serum creatinine level at one year was not signif-
icantly different than that measured preoperatively (1.18
0.32 vs. 1.20  0.36, P  .87). Beyond one year, no
aneurysm rupture, conversion to open repair, or coronary
intervention occurred. During follow-up year 2, MAEs
include coronary artery bypass grafting (n 1), myocardial
infarction treated medically (n  1), and stroke (n  1) in
a patient who suffered a stroke during year 1. Mean serum
creatinine level at two years remained stable (1.20  0.28
Fig 3. Kaplan Meier Plot – freedom from all cause mortality.vs. 1.20  0.36, P  1.00). As illustrated in Fig 4, theKaplan-Meier one-year estimate of freedom from MAE is
79%.
Other treatment effectiveness measures
Aneurysm sac exclusion. The Core Laboratory as-
sessed CT scans to determine the effectiveness of aneurysm
sac exclusion, as measured by maximum diameter changes
over time. Consistent with reporting standards, aneurysm
sac diameter decrease or increase was defined as a change of
5 mm compared with baseline.9 A summary of the results
through one year is presented in Table IV. In aggregate,
96% of patients had no growth in the aneurysm sac diame-
ter (stable: 66%; significantly reduced: 30%). Two patients
were identified with an increase in aneurysm sac diameter at
one year and at two years. One patient was diagnosed with
a Type II endoleak at the one and six month visits that
resolved. A second patient was diagnosed with a Type II
endoleak at one month, six months, and one year. No
intervention has been required. Overall, mean aneurysm
sac diameter was reduced at one year and two years com-
pared with the baseline measurement (5.5  0.9 cm vs.
5.7 1.0 cm [P .21] and 5.3 1.0 cm vs. 5.7 1.0 cm
[P  .09], respectively). No migration (device movement
10 mm relative to the original implant location) has been
observed. However, limited device movement of 5 mm at
one year was identified in two patients who had thrombus-
filled reverse taper necks that were 10 mm, neither of
which has been observed with an MAE or an endoleak.
Device integrity. The Core Laboratory assessed ab-
dominal x-rays and CT scans to evaluate device integrity,
including stent fracture, stent graft patency, and limb oc-
clusion. Throughout the follow-up period, no stent frac-
tures or limb occlusions have been observed. Stent graft
patency of 100% is observed at every follow-up timepoint.
Endoleak and secondary procedures. The Core Lab-
oratory assessed CT scans to determine the presence of
endoleak at each follow-up. Results are presented in Table
V. The majority of endoleaks (27/31) are Type II. More-
over, there have been no Type III or Type IV endoleaks.
Through current follow-up, a total of five patients have
undergone a secondary procedure for endoleak of any type
(Table VI). One secondary intervention was performed
within 30 days, for an early secondary procedure rate of
1.3% (1/78). Attributed by the investigator to extreme
tortuosity and narrowing at the native bifurcation, this
patient was observed with kinking of the device within the
stent graft limbs and at the level of the bifurcation, with
associated distal Type I endoleak. On postoperative day
seven, stenting and ballooning of the iliac vessels to the
level of the aortic bifurcation and within the stent graft
lumen was performed, resolving the kinking and endoleak.
After 30 days and within one year, the secondary procedure
rate was 5.1% (4/78). One patient with bilateral distal Type
I endoleak received a limb extension (left iliac) and under-
went angioplasty (right iliac) on postoperative day 51,
successfully repairing the leaks. One patient diagnosed with
Type II endoleak associated with both IMA and lumbar
vessels underwent attempted embolization on days 176,
leak w
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diagnosed during follow-up year two to have a proximal
Type I endoleak, and received a balloon-expandable aortic
stent on day 768, which resolved the endoleak.
DISCUSSION
A prospective clinical trial was conducted under an
FDA-approved protocol to evaluate the safety and effec-
tiveness of anatomical fixation using the Powerlink 28 mm
bifurcated device with concomitant proximal sealing using
the Powerlink XL 34 mm proximal extension in the treat-
ment of abdominal aortic or aorto-iliac aneurysms (AAA).
Notably, this is the first trial conducted using this distal
fixation/proximal sealing technique. Additional data were
gathered under a continued access provision of the proto-
col. Perioperatively, no mortality, aneurysm rupture, or
conversion to open repair occurred. Procedural complica-
tions and major adverse events were limited. Through one
Table III. Major adverse events within one year*
Event Within 30 days [n/N (%)]
Patients with 1 event 3/78 (3.8%)
Mortality 0/78 (0.0%)
AAA rupture 0/78 (0.0%)
Conversion to open repair 0/78 (0.0%)
Coronary intervention 0/78 (0.0%)
Myocardial infarction 0/78 (0.0%)
Renal failure 1/78 (1.3%)
Respiratory failure 1/78 (1.3%)
Secondary procedure 1/78 (1.3%)
Stroke 0/78 (0.0%)
Results shown as number of patients with event (% of total in group).
AAA, Abdominal aortic aneurysm.
*Defined as all-cause death, aneurysm rupture, conversion to open repair
secondary procedure for proximal type I endoleak, and stroke.
†Includes one patient who underwent three interventions for Type II endo
during follow-up year two.
Fig 4. Kaplan Meier Plot – freedom from major adverse events.year and currently available follow-up, no aneurysm-relatedmortality, aneurysm rupture, or conversion to open repair
has occurred. All-causemortality is consistent with previous
trial results. The overall major adverse event rate at 30 days
and at one year was 3.8% (3/78) and 14% (11/78), respec-
tively. These results compare favorably with corresponding
rates observed in the original Powerlink trial (6.8% and
17%, respectively)1 suggesting satisfactory utilization of the
aortic bifurcation for fixation even with large proximal
aortic necks. The main body graft resting on the aortic
bifurcation can support the added mechanical forces of a
larger (34 mm) cuff inside a standard size (28 mm) body.
Trial success was demonstrated with the prevention of
proximal Type I endoleak at one year in more than 96% of
the patients enrolled, leading to US FDA approval of this
device and treatment algorithm in October 2008. More-
over, no migration has occurred and no renal artery infarct
or occlusion has occurred as these aneurysms have begun to
shrink over time. Outcomes of secondary endpoints such as
clinical utility measures (ie, operative time, blood loss,
hospital stay) and device related variables (ie, delivery suc-
cess, aneurysm sac changes over time, and device integrity)
provide supportive evidence as to the safety and effective-
ness of this treatment algorithm for patients with aortic
necks up to 32 mm in diameter.
The Powerlink system is unique among EVAR devices
currently available in that the bifurcated stent graft is of a
unibody design. Delivery is achieved through only one
surgically exposed femoral artery for deployment, with a
precannulated contralateral limb with guidewire compati-
ble with percutaneous 9 Fr sheath placement. This design
enables it to be used in patients with one small or diseased
iliac access vessel, potentially broadening the population of
patients that can be treated endovascularly. Within this trial
population, the 16 mm bifurcated device limbs were placed
within native vessels per the device design intent ranging in
diameter from 10 mm to 14 mm. Patients with larger iliac
vessels were treated with larger diameter limb extensions.
The lack of limb thrombosis or occlusion serves to reinforce
30 days to one year [n/N (%)] Total [n/N (%)]
11/78 (14%) 13/78 (17%)
5/78 (6.4%) 5/78 (6.4%)
0/78 (0.0%) 0/78 (0.0%)
0/78 (0.0%) 0/78 (0.0%)
0/78 (0.0%) 0/78 (0.0%)
1/78 (1.3%) 1/78 (1.3%)
3/78 (3.8%) 4/78 (5.1%)
1/78 (1.3%) 2/78 (2.6%)
2/78 (2.6%)
†
3/78 (3.8%)
2/78 (2.6%) 2/78 (2.6%)
nary intervention, myocardial infarction, renal failure, respiratory failure,
ithin one year and subsequent intervention for Type I proximal endoleak, corothe validity of this device design.
5 m
and 37
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the aortic bifurcation enables fixation of the main device
independently from sealing at the proximal neck and distal
iliac seal zones. The core laboratory reportedmigration rate
of 0% in this cohort provides substantial reinforcement for
themid-term durability of this approach. In their analysis of
the original Powerlink trial in patients with aortic necks up
to 26 mm in diameter, Wang et al5 identified a migration
rate of 1.6% within one year, and 2.6% beyond one year
through five years. Among all of these patients, two (1.0%
of the cohort) required an intervention for endoleak. These
authors determined that each of the eight migrations oc-
curred in patients who did not receive the device via ana-
tomical fixation. This finding has been echoed by Qu et
al,10 wherein a Powerlink migration rate of 1.9% over a
seven-year period was observed. Consistently, all of the
migrations occurred in patients in whom the bifurcated
devices were not placed at the aortic bifurcation, but still
remains lower compared with rates between 9.5% and 17%
reported for other endografts within four years.11-13 To
this end, some have focused efforts on improving proximal
endograft fixation usingmechanical means, including radial
force, suprarenal fixation, or penetrating hooks and barbs;
however, the problem remains. Others recognize that distal
Table IV. Aneurysm sac diameter results (Core Laborator
Time point Decreased n/N (%) Stabilized n
One year 16/51 (31%) 33/51 (
Two years 7/15 (47%) 6/15 (
Decreased: 5 mm reduction; Stabilized: 5 mm or less change; Increased:
Table V. Endoleak results (Core Laboratory)
Any endoleak Type I proximal Type I dista
One month (N  73)
17 (23%) 0 (0.0%) 1 (1.4%)
One year (N  51)
10 (20%) 1 (2.0%) 1 (2.0%)
Two years (N  15)
4 (27%) 0 (0.0%) 0 (0.0%)
Table VI. Secondary procedures
Time point
Type I proximal endoleak
†
n/N (%)
Type
One month 0/78 (0.0%) 1
Six months 1/75 (1.3%) 1
One year 1/56 (1.8%) 0
Two years 1/22 (4.5%) 0
A total of five patients underwent one or more intervention.
†Three patients underwent successful intervention on days 66, 393 and 768
‡Two patients underwent successful intervention on days seven and 51, res
¥One patient underwent three unsuccessful interventions on days 176, 194,
two that successfully resolved a proximal Type I endoleak.sealing is essential to ensuring the stability of stent graftpositioning over time.14,15 The absence of migration in this
trial population is even more remarkable considering the
prevalence of challenging anatomy in these patients having
wide aortic necks. Suprarenal endograft fixation has been
advocated as a potential means of treating patients with
short aortic necks because in theory less infrarenal neck is
required to generate an adequate seal.7 In addition, a
thrombus-filled infrarenal aortic neck places patients un-
dergoing endovascular repair with an infrarenal device re-
quiring proximal fixation at increased risk for device migra-
tion and/or poor sealing.8 The presence of a conical or
reverse conical aortic neck adds a further obstacle to achiev-
ing fixation and proximal seal. It is clear that use of more
distal fixation by seating the bifurcated stent graft at the
aortic bifurcation with concomitant sealing at distal and
proximal zones effectively preventsmigration. As evidenced in
the results, this treatment algorithm was well tested in this
trial enrolling patients with wide aortic necks and prevalent
hostile proximal neck anatomical features that are recog-
nized risk factors for migration. However, ultimately,
longer term results will be required to assure the security of
this fixation method.
The rate of secondary endovascular procedures for
repair of Type I or Type II endoleak was 6.4%. Stent graft
%) No growth n/N (%) Increased n/N (%)
49/51 (96%) 2/51 (3.9%)
13/15 (87%) 2/15 (13%)
m increase; No Growth  Decreased  Stabilized.
Type II Type III Type IV Unknown
14 (19%) 0 (0.0%) 0 (0.0%) 3 (4.1%)
9 (18%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
4 (27%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
al endoleak
‡
(%)
Limb occlusion
n/N (%)
Type II endoleak
¥
n/N (%)
(1.3%) 0/78 (0.0%) 0/78 (0.0%)
(1.3%) 0/75 (0.0%) 1/75 (1.3%)
(0.0%) 0/56 (0.0%) 1/56 (1.8%)
(0.0%) 0/22 (0.0%) 0/22 (0.0%)
ectively.
ly.
5. This patient underwent a subsequent intervention during follow-up yeary)
/N (
65%)
40%)lI dist
n/N
/78
/75
/56
/22
, resp
pectiveocclusion was not observed in this trial; this is in contrast to
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citing a 7.2% event rate.16 The overall reintervention rate
observed in this trial compares favorably with the one-year
rates observed in the original Powerlink trial and trials of
other devices (8.0% to 10%).1,11-13 Notably, although all
patients in this trial received a bifurcated device and one or
more proximal extensions, no Type III endoleaks were
observed. Effective aneurysm exclusion at one year is fur-
ther demonstrated by the lack of aneurysm growth in 96%
of patients. Consistent with all other Powerlink trials, no
stent or graft material fatigue or failure or Type IV endoleak
has been observed.
CONCLUSIONS
The combination of an anatomically-fixed Powerlink
bifurcated 28 mm stent graft and a Powerlink XL 34 mm
proximal extension appears safe and effectively excludes
aneurysms in patients with wide aortic necks. The require-
ment for only one surgically exposed femoral artery facili-
tates graft placement in patients with limited access routes.
As in prior Powerlink trial reports, the graft and stent
materials have been free from failure and fatigue. The
absence of aneurysm-related death, conversion to open
repair, and migration through one year in this pivotal trial
underscore the significant clinical benefits of this endovas-
cular treatment algorithm particularly in light of the prev-
alent hostile neck anatomy. Longer term follow-up will
determine the durability of these results.
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